版本:
中国

BRIEF-Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

March 10 Galapagos Nv

* announces two new phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease

* studies are being led by filgotinib collaboration partner Gilead Sciences Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐